Working… Menu

A Two-year Study of Telbivudine in HBeAg Negative Hepatitis (STEN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01521975
Recruitment Status : Completed
First Posted : January 31, 2012
Last Update Posted : October 24, 2017
Guangdong Provincial People's Hospital
Guangzhou 8th People's Hospital
Information provided by (Responsible Party):
Chao-Shuang Lin, Third Affiliated Hospital, Sun Yat-Sen University

Brief Summary:
Based on GLOBE study supplying predictability analysis results, ROADMAP strategy provides an individualized telbivudine treatment roadmap strategy designed to achieve optimal viral suppression and low resistance rate in patients with chronic hepatitis B(CHB), which includes adding ADV treatment at different time points according to individual patient response. China CHB Guidelines (China Medical Association 2010) make impress on and confirm LDT ROADMAP strategy particularly, which may be a large potential to expand the naïve patients. We are lack of optimal model in HBeAg(-). In China HBeAg(-) is around 38% of total CHB patients. In GLOBE study, LdT treatment against HBeAg(-) patients with HBV DNA <7log showed a good 2 year efficacy, but we still look forward to more efficient treatment and lower resistance rate. This study complies with the principle of individualized therapy recommended and ethical principles. It is expected that this study design with individualized treatment approach may improve efficacy and lower the resistance rates. In addition, it will provide important information on how to bring greater benefits to patients with CHB.

Condition or disease Intervention/treatment Phase
Hepatitis B, Chronic Drug: Telbivudine, Adefovir dipivoxil Phase 4

Detailed Description:
This study is an open-label, multicenter, PCR response adaptive clinical study design, with intensification of treatment (addition of adefovir to telbivudine treatment) depending on HBV DNA level at week 24. All patients commence with Telbivudine 600mg daily. At week 24 they will be divided into 2 Groups according to virological response. Patients with PCR detectable HBV DNA will add on ADV(Group I). Patients with PCR undetectable HBV DNA(Group II)will continue telbivudine monotherapy. ADV will not be added on unless viral breakthrough occurs.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 360 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Two-year, Open-label, Virological Response Adaptive Design, Multicenter Study to Evaluate Efficacy of Telbivudine in HBeAg Negative Adult CHB Patients With Roadmap Strategy
Actual Study Start Date : January 1, 2011
Actual Primary Completion Date : February 28, 2014
Actual Study Completion Date : May 30, 2014

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: HBeAg Negative Hepatitis
HBeAg Negative Hepatitis patients.
Drug: Telbivudine, Adefovir dipivoxil
All patients will take Telbivudine 600 mg PO daily from baseline. Some patients will take Adefovir dipivoxil 10 mg PO daily if they meet the criteria of adding Adefovir dipivoxil.
Other Name: Sebivo, LDT

Primary Outcome Measures :
  1. The percentage of patients with undectable HBV DNA [ Time Frame: at Week 104 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Detectable serum HBsAg at the Screening visit and at least 6 months prior
  • HBeAg negative at Screening visit
  • serum HBV DNA level >2,000 IU/mL at Screening visit
  • Elevated serum ALT≥2 ×ULN and <10×ULN at Screening visit (excluding ALT elevations due to non-HBV reasons such as drug, alcohol etc)

Exclusion Criteria:

  • Patient has a history of clinical signs/symptoms of hepatic decompensation (Child-Pugh Grade B or C) or ascites, esophageal variceal bleeding, hepatic encephalopathy, or spontaneous bacterial peritonitis.
  • Patient has a history of hepatocellular carcinoma (HCC) or suspected symptoms of HCC, such as suspicious foci on imaging studies and/or serum alpha-fetoprotein (AFP)>50ng/mL.
  • Patient has received treatment of nucleoside or nucleotide drugs whether approved or investigational before.
  • Patient has received IFN or other immunomodulatory treatment within 52 weeks before Screening.
  • Patient has a medical condition that requires frequent use of systemic acyclovir or famciclovir.
  • Patient has a medical condition that requires frequent use of systemic corticosteroids, however topical and inhaled corticosteroids are allowed.
  • Patient has used hepatotoxic drugs within one month.
  • Patient has overtaken alcohol (>40g/day) or abused illicit drugs in recent one year.
  • Use of other investigational drugs at the time of enrollment.
  • History of hypersensitivity to any of the study drugs (telbivudine or adefovir).
  • Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive urine pregnancy test.
  • Patient is co-infected with HCV, HDV or HIV.
  • Patient has one or more additional known primary or secondary causes of liver disease, other than hepatitis B (e.g., alcoholism, autoimmune hepatitis).
  • History of malignancy of any organ system.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01521975

Layout table for location information
China, Guangdong
The Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China, 510630
Sponsors and Collaborators
Third Affiliated Hospital, Sun Yat-Sen University
Guangdong Provincial People's Hospital
Guangzhou 8th People's Hospital
Layout table for investigator information
Principal Investigator: Zhi-Liang Gao, Prof Third Affiliated Hospital, Sun Yat-Sen University

Layout table for additonal information
Responsible Party: Chao-Shuang Lin, Professor, Third Affiliated Hospital, Sun Yat-Sen University Identifier: NCT01521975     History of Changes
Other Study ID Numbers: HBeAg negative Roadmap
First Posted: January 31, 2012    Key Record Dates
Last Update Posted: October 24, 2017
Last Verified: January 2011
Keywords provided by Chao-Shuang Lin, Third Affiliated Hospital, Sun Yat-Sen University:
HBeAg negative hepatitis
Additional relevant MeSH terms:
Layout table for MeSH terms
Hepatitis A
Hepatitis B
Hepatitis B, Chronic
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Hepadnaviridae Infections
DNA Virus Infections
Hepatitis, Chronic
Adefovir dipivoxil
Antiviral Agents
Anti-Infective Agents
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Retroviral Agents